Evidence map›Paper›PMID 34395911›Full record

ArticleOpen life sciences2021

Effects of miR-185-5p on replication of hepatitis C virus.

Wei Huang, Lingyan Song, Jingyan Zhang, Xueqiang Yan, Hui Yan

Open access · goldAbstract read
In one paragraph

Article in Open life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wei HuangDepartment of Laboratory Medicine, Heping Hospital Affiliated to Changzhi Medical College, No. 110 Yan'an Nan Road, Changzhi 046000, China.
Lingyan SongDepartment of Laboratory Medicine, Heping Hospital Affiliated to Changzhi Medical College, No. 110 Yan'an Nan Road, Changzhi 046000, China.
Jingyan ZhangDepartment of Laboratory Medicine, Heping Hospital Affiliated to Changzhi Medical College, No. 110 Yan'an Nan Road, Changzhi 046000, China.
Xueqiang YanDepartment of Laboratory Medicine, Heping Hospital Affiliated to Changzhi Medical College, No. 110 Yan'an Nan Road, Changzhi 046000, China.
Hui YanDepartment of Laboratory Medicine, Heping Hospital Affiliated to Changzhi Medical College, No. 110 Yan'an Nan Road, Changzhi 046000, China.
Changzhi Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article was designed to explore the effects and mechanisms of miR-185-5p on the replication of hepatitis C virus (HCV). Quantitative reverse transcription PCR (qRT-PCR) was performed for detecting the abundance of miR-185-5p and HCV RNA in HCV-infected primary hepatocytes and Huh7.5 cells. Dual-luciferase reporter gene assay was used for exploring the interaction between miR-185-5p and GALNT8. Western blot analyzed protein expression of GALNT8, NS3, and NS5A. miR-185-5p was remarkably downregulated in HCV-infected primary hepatocytes and Huh7.5 cells. miR-185-5p upregulation inhibited HCV RNA expression, while its inhibition promoted HCV replication. miR-185-5p induced accumulation of NS3 and NS5A in the cells. Dual-luciferase reporter gene assay verified the targeted relationship between miR-185-5p and GALNT8. In addition, the effects of overexpressing or knocking down miR-185-5p on HCV replication could be correspondingly eliminated by the overexpression or knockdown of GALNT8. miR-185-5p may target GALNT8 in JFH1-infected Huh7.5 cells and then inhibit HCV replication. miR-185-5p may be a potential target for treating HCV.

Indexed as

GALNT8hepatitis C virusmiR-185-5preplication

Identifiers

PMID34395911
PMCPMC8330614
OpenAlexW3190330777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.